- Home
- BNL vs VKTX Comparison
BNL vs VKTX Comparison
Compare BNL & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNL
- VKTX
- Stock Information
- Founded
- BNL 2007
- VKTX 2012
- Country
- BNL United States
- VKTX United States
- Employees
- BNL N/A
- VKTX N/A
- Industry
- BNL Real Estate Investment Trusts
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- BNL Real Estate
- VKTX Health Care
- Exchange
- BNL Nasdaq
- VKTX Nasdaq
- Market Cap
- BNL 3.5B
- VKTX 3.5B
- IPO Year
- BNL 2020
- VKTX 2015
- Fundamental
- Price
- BNL $18.59
- VKTX $24.09
- Analyst Decision
- BNL Hold
- VKTX Strong Buy
- Analyst Count
- BNL 6
- VKTX 12
- Target Price
- BNL $18.50
- VKTX $87.50
- AVG Volume (30 Days)
- BNL 1.6M
- VKTX 9.8M
- Earning Date
- BNL 10-29-2025
- VKTX 10-22-2025
- Dividend Yield
- BNL 6.18%
- VKTX N/A
- EPS Growth
- BNL N/A
- VKTX N/A
- EPS
- BNL 0.52
- VKTX N/A
- Revenue
- BNL $442,203,000.00
- VKTX N/A
- Revenue This Year
- BNL $4.91
- VKTX N/A
- Revenue Next Year
- BNL $5.88
- VKTX N/A
- P/E Ratio
- BNL $36.19
- VKTX N/A
- Revenue Growth
- BNL 3.85
- VKTX N/A
- 52 Week Low
- BNL $13.96
- VKTX $18.92
- 52 Week High
- BNL $19.15
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- BNL 67.19
- VKTX 34.76
- Support Level
- BNL $18.41
- VKTX $24.82
- Resistance Level
- BNL $18.75
- VKTX $26.50
- Average True Range (ATR)
- BNL 0.23
- VKTX 1.27
- MACD
- BNL -0.04
- VKTX -0.17
- Stochastic Oscillator
- BNL 66.03
- VKTX 5.54
About BNL Broadstone Net Lease Inc.
Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.